ZeeCRO Sells Bioanalytical Division

Tuesday, December 29, 2009 07:42 AM

Cary, N.C.-based contract research organization (CRO) ZeeCRO, formerly AAIPharma Services, sold its bioanalytical division to Kansas Venture Capital, Inc., (KVCI) for an undisclosed sum. KCVI plans to grow the bioanalytical business, which is now a new company, KCAS, Inc.

ZeeCRO streamlined operations to focus on its CRO business in October by selling off its pharmaceutical development services business. As part of that sale, the company lost the rights to the AAIPharma name.  According to ZeeCRO’s web site, the CRO continues to offer early- and late-stage development services to global customers. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs